676 results about "Virulence" patented technology

The invention discloses a capture probe group for detecting pathogenic microorganisms and application of the capture probe group. The nucleic acid sequence of the capture probe group comprises a sequence as shown in SEQ ID NO. 1 to SEQ ID NO. 101. The capture probe group can cover and detect 119 types of bacteria, 32 types of fungi, 41 types of DNA viruses and 71 types of RNA viruses and covers common infectious disease pathogens, the kit containing the capture probe can cover and detect 88 types of drug-resistant and virulence genes, the detection performance of pathogenic microorganisms is greatly improved, and the sensitivity and specificity are improved.

The invention relates to the technical field of biology, in particular to a verticillium dahliae virulence gene, a verticillium dahliae virulence protein and application. The invention discloses a verticillium dahliae virulence gene VdPHO23like. The verticillium dahliae virulence gene VdPHO23like comprises a polynucleotide sequence for coding an amino acid sequence of SEQ ID NO: 3. According to the invention, expression of the gene is inhibited in a targeted manner through an RNA interference mediated gene silencing technology so as to weaken virulence of pathogenic bacteria, and an efficient, specific and environment-friendly comprehensive prevention and control strategy is provided for verticillium wilt of crops such as cotton.

The invention discloses a biological hazard big data analysis and monitoring early warning system, and relates to the technical field of public health safety, and an analysis subsystem in the system comprises a core logic module comprising a quality control unit, an error correction unit, an assembly unit and a box separation unit; the unit analysis module comprises a pathogen analysis unit, a resistance gene unit, a virulence evaluation unit and an evolution development unit; the flora integrated analysis module comprises a traceability analysis unit, a mutation characteristic unit, a propagation evolution unit and a transformation management and control unit; the early warning subsystem comprises a risk assessment and early warning system design unit, a dynamic research and propagation analysis unit, an assessment model construction unit, a pathogen evolution and function research unit, a toxicity and propagation risk comprehensive prediction unit, a pathogen risk monitoring network unit and an unknown pathogen and potential risk identification unit. According to the method, the biological hazard data can be comprehensively, efficiently and accurately analyzed.

The invention discloses a virulence-attenuated bovine nodular skin disease virus LSDV-75 and application thereof, and belongs to the technical field of attenuated strains. The invention aims to provide a bovine nodular skin disease virus vaccine strain which is sufficient in attenuation and good in immune effect. The invention provides a virulence-attenuated bovine nodular skin disease virus strain, which is named as sheep pox virus LSDV-75, has the preservation number of CCTCC NO: V2024114, and is preserved in the China Center for Type Culture Collection on December 2, 2024. The vaccine strain provided by the invention can be used as a vaccine candidate strain for safely and effectively preventing and controlling bovine nodular dermatosis.

The invention belongs to the field of animal vaccines, and particularly relates to a multi-epitope fusion protein aiming at multi-serotype laisseria parasuis antigen and application. The applicant carries out proteomics analysis on four clinical isolated strains of serotypes 4, 5 and 13 of the parasuis leather serotype 4, 5 and 13 with high toxicity and good immunogenicity, and eight antigen proteins are screened out of the four clinical isolated strains of the serotypes 4, 5 and 13 of the parasuis leather serotype 4, 5 and 13. And further analyzing the screened eight antigen proteins to finally obtain the antigen multi-epitope fusion protein with immunogenicity capable of recognizing three serotypes. When the fusion protein is used as a vaccine, the protection rate of clinically separated piglets infected with a serum type 4 strain HB04, a serum type 5 strain SJZ05 and a serum type 13 strain GD20 reaches 100%.

The invention discloses a virulence-attenuated bovine nodular skin disease virus LSDV DQ and application thereof, and belongs to the technical field of attenuated strains. The invention aims to provide a bovine nodular skin disease virus vaccine strain which is sufficient in attenuation and good in immune effect. The invention provides a virulence-attenuated bovine nodular skin disease virus strain, which is named as sheep pox virus LSDV-DQ, has the preservation number of CCTCC NO: V2024113, and is preserved in the China Center for Type Culture Collection on December 2, 2024. The vaccine strain provided by the invention can be used as a vaccine candidate strain for safely and effectively preventing and controlling bovine nodular dermatosis.

The invention provides a Villonella enteritidis strain and an application of the Villonella enteritidis strain. The preservation number of the Villonella enteritidis strain is GDMCC No: 65234. The invention also provides a preparation containing the Wehonor enteritidis, a culture method and application of the Wehonor enteritidis as a labeled microorganism or a target spot in preparation of drugs for screening diseases caused by the Wehonor enteritidis. According to the present invention, the virulence gene and the pathogenicity of the Wehonor enteritidis are analyzed, such that the Wehonor enteritidis has the potential pathogenicity for aggravating the inflammatory bowel disease, and the strain provides specificity in the aspects of biological characteristics, pathogenicity and the like compared with the Wehonor micrococcus, such that the cognition of the Wehonor micrococcus in the intestinal tract is new improved, and the Wehonor micrococcus enteritidis can be used for the treatment of the inflammatory bowel disease. Moreover, a new view angle and a new direction are provided for research on the effect of the Wehonor coccus in the intestinal diseases such as IBD (Infectious Bursal Disease).

The invention relates to the technical field of public health safety, and discloses a quantitative evaluation method and system for pathogen transmission risk, and the evaluation method comprises the following steps: step 1, obtaining virulence genes, reference virulence genes, environmental parameters, transmission factors and host risk factor parameters of pathogen samples; 2, performing variation detection on the virulence gene by adopting various variation detection algorithms to obtain all variation sites, and processing all variation sites to obtain effective variation sites; 3, constructing a virulence index model, inputting the variation distance into the virulence index model, and calculating the virulence index of the pathogenic bacteria sample; and 4, constructing a propagation risk assessment model, inputting the virulence index, the environmental factor, the propagation coefficient and the host susceptibility risk index into the propagation risk assessment model, and outputting a risk value by the propagation risk assessment model. According to the method, accurate prediction of the pathogen transmission risk can be realized.

The invention relates to the technical field of high-throughput targeted sequencing, in particular to a primer group for detecting important drug-resistant genes and virulence genes of multi-drug-resistant pathogenic bacteria and application of the primer group. Specifically, the kit comprises detection primers for multiple drug-resistant bacteria such as third-generation cephalosporin drug-resistant enterobacteriaceae bacteria, carbapenem drug-resistant enterobacteriaceae bacteria, carbapenem drug-resistant acinetobacter baumannii, rifampicin drug-resistant mycobacterium tuberculosis and the like. The method has the technical advantages of rapidness, high efficiency, strong targeting property, strong specificity and the like, is suitable for epidemic and difference analysis of various important drug-resistant genes and virulence genes carried by metagenome samples of various environments or disease materials and the like, evaluates the risk of related environments on the basis, and can further guide prevention and clinical treatment medication.

The invention discloses an application of phloretin in preparation of a medicine or a feed additive for treating or preventing swine envelope virus infection, the medicine is phloretin or oral liquid, granules, tablets and powder prepared from phloretin as an effective component and a solvent or an auxiliary material, and the use dosage is 2.5-10mg / kg of the body weight of a pig; or the phloretin is directly added into the feed, and the addition amount of the phloretin is 0.01-0.03% of the total weight of the pig feed. The phloretin or the composition containing the phloretin is used as a medicine or a feed additive, is high in safety and free of toxic and side effects, and has the effects of remarkably inhibiting replication of envelope viruses such as porcine epidemic diarrhea virus, porcine reproductive and respiratory syndrome virus and African swine fever virus and reducing the toxicity of the porcine envelope viruses; the defects of immune failure possibly caused by vaccination, virus variation caused by use of antiviral drugs and the like are overcome, the morbidity and mortality of the piglets infected with the swine envelope virus are effectively reduced, and the effect of preventing and treating or preventing the swine envelope virus infection diseases is achieved.

The invention discloses a lytic bacteriophage vBVpaSR40Z and application of the lytic bacteriophage vBVpaSR40Z to prevention and control of vibrio parahaemolyticus in an aquaculture environment. The preservation number of the vibrio parahaemolyticus phage vBVpaSR40Z is as follows: GDMCC No: 67440-B1, and the vibrio parahaemolyticus phage vBVpaSR40Z is The R40Z can be used for cracking multiple strains of vibrio parahaemolyticus and vibrio alginolyticus, has the capability of adapting to an aquaculture environment, and keeps relatively high activity within the range of 4-25 DEG C and pH of 4-10; no virulence gene or drug-resistant gene is detected through genome analysis, and phylogenetic and whole genome comparison shows that the similarity between R40Z and a related phage is lower than a species level threshold value, so that R40Z is a new phage species; the R40Z can obviously inhibit the growth of a host under various infection complex numbers. The R40Z has the advantages of strong splitting capacity, good environmental stability, high genome safety, unique evolutionary characteristics and the like, and is an aquatic vibriosis biological prevention and control bacteriophage with application potential.

The invention relates to the technical field of microorganisms, in particular to a bacteriophage capable of splitting a high-risk escherichia coli clone strain and targeting multiple serotypes and application of the bacteriophage. The invention discloses a bacteriophage capable of splitting a high-risk escherichia coli clone strain and targeting multiple serotypes, the bacteriophage is named as Escherichia phage vBEcoM32M3Y, the bacteriophage is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.45969. The invention further discloses a preparation method of the bacteriophage. The bacteriophage disclosed by the invention is low in MOI, good in stability, good in cracking activity, free of drug-resistant and virulence genes in a genome sequence, and relatively good in clinical application value.

The invention provides a lactobacillus pentosus and a preparation method and application of bacteriocin of the lactobacillus pentosus. The name of the strain is lactobacillus pentosus YCL31, and the strain is preserved in Guangdong Microbial Culture Collection Center (GDMCC) on June 25, 2025, the preservation address is the 5th floor of the building 59, No. 100 courtyard, Xianlie Middle Road, Guangzhou, and the preservation number is GDMCC No: 66589. The bacteriocin separated and purified from the metabolite of the bacterium can destroy the morphological structure of the vibrio parahemolyticus and inhibit the toxicity of the vibrio parahemolyticus, can also achieve the effect of remarkably inactivating the vibrio parahemolyticus in a metapenaeus ensis system, can effectively delay the spoilage of the metapenaeus ensis, and has a good application prospect as a bacteriostatic agent or preservative. Therefore, development and application of the novel bacteriocin have important reference value in related fields.

A bacteriophage for specifically lysing high-virulence capsular Klebsiella pneumoniae, pertaining to the field of microorganisms. The deposit number of the Klebsiella pneumoniae bacteriophage vB_kpnP_D39 is CCTCC NO: M 2024690. In the bacteriophage liquid formulation prepared on the basis of the bacteriophage, the working titer of the bacteriophage is greater than 1 × 109 PFU / mL. The bacteriophage has high specificity and can kill all high-virulence multidrug-resistant Klebsiella pneumoniae of K1, K2, and K57 capsular serotypes, with an adsorption efficiency of 99.60%. The bacteriophage exhibits a biofilm clearance rate of 47.4%-63.2% and a capsule clearance rate of 42.1%-60.6% against the high-virulence Klebsiella pneumoniae. The bacteriophage is expected to become a safe, non-toxic agent for the prevention, control, and treatment of high-virulence multidrug-resistant Klebsiella pneumoniae infections, or an antibiotic adjuvant.

The invention discloses a method and system for detecting respiratory tract pathogens, pathogen drug-resistant genes and pathogen virulence genes, and relates to the technical field of gene detection.The method comprises the steps that a respiratory tract sample of a patient is collected, DNA and RNA are extracted, and total nucleic acid is obtained; carrying out first-round PCR amplification on the total nucleic acid, purifying a first-round PCR product, carrying out second-round PCR amplification, and sorting the product to obtain a library building product; performing high-throughput sequencing on the library building product to obtain sequencing data, and detecting pathogens, drug-resistant genes and virulence genes; according to the method and system for detecting the respiratory tract pathogens, the pathogen drug-resistant genes and the pathogen virulence genes, by optimizing library preparation and direct library building of nucleic acid, the process is simplified, and efficiency and accuracy are improved; the balance reagent design guarantees library quality; the kit adapts to pathogen detection requirements in Yunnan and the like, provides efficient diagnosis, shortens detection time, improves treatment effect, regularly updates pathogen information, and keeps technical frontier.

The invention discloses trichoderma asperellum TR35 and application thereof in inhibition of mulberry bacterial wilt and prevention and treatment of mulberry bacterial wilt, the trichoderma asperellum TR35 is identified as Trichoderma asperellum, the trichoderma asperellum TR35 is preserved in Guangdong Microbiological Culture Collection Center, the preservation number is GDMCC No.64886, and the preservation time is July 18, 2024. The trichoderma asperellum TR35 obtained through separation and screening has good inhibition and antagonism effects on mulberry ralstonia solanacearum, and can be used for preventing and treating mulberry bacterial wilt. The inhibition rate of the trichoderma asperellum TR35 to the mulberry ralstonia solanacearum reaches up to 98.25%, and the active fermentation liquor of the trichoderma asperellum TR35 not only can significantly inhibit the growth of the ralstonia solanacearum and reduce the forming ability of a biological membrane, but also can destroy the integrity and continuity of the biological membrane of the ralstonia solanacearum. In addition, the bacterial zone of the ralstonia solanacearum can be reduced, the athletic ability is reduced, and the expression of virulence-related genes in the ralstonia solanacearum is remarkably inhibited.

The invention belongs to the technical field of microorganisms, and particularly relates to bacillus thuringiensis ZR-560 and application thereof, the bacillus thuringiensis ZR-560 is preserved in China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.30586. The invention further discloses a preparation method of the bacillus thuringiensis ZR-560. The bacillus thuringiensis ZR-560 strain provided by the invention has high insecticidal toxicity, and the parasporal crystal protein preparation of the bacillus thuringiensis ZR-560 strain has a corrected death rate of 100% for spodoptera frugiperda, ostrinia nubilalis, prodenia litura and beet armyworm, and is a Bt strain with a relatively broad-spectrum insecticidal effect.

The invention relates to the technical field of microorganisms, in particular to pediococcus pentosaceus for degrading silage fumonisins and application of the pediococcus pentosaceus. The pediococcus pentosaceus is preserved in the General Microbiological Culture Collection Center of the China Committee for Culture Collection of Microorganisms, and the preservation number of the pediococcus pentosaceus is CGMCC No. 28710. The pediococcus pentosaceus is high in growth rate, high in acid production efficiency, good in acid resistance and salt resistance, capable of well utilizing different types of carbon sources for fermentation, high in adaptive capacity and free of virulence genes commonly having toxic effects on livestock, the pediococcus pentosaceus serves as a pasture silage additive, the fermentation type is homotype fermentation, and the application range is wide. The pH value of the silage can be rapidly reduced, generation of ammoniacal nitrogen is reduced, the content of fumonisins is efficiently reduced, the fermentation quality of the silage is improved, and wide application prospects are achieved.

The present invention is in the field of agricultural pathogen control. Methods and compositions are described for controlling plant diseases caused by pathogens, including fungi and oomycete phytopathogens. Chemicals were screened for activity as autophagy inhibitors. The screening method used a bioluminescence resonance energy transfer (BRET)-based high-throughput screening strategy to identify compounds that inhibit fungal ATG4 cysteine protease-mediated cleavage of ATG8 for autophagosome formation. Ebselen and ebselen analogs were identified as inhibitors of fungal pathogens ATG4-mediated ATG8 processing. Identified chemicals inhibit spore germination, hyphal development, and appressorium formation. The autophagy inhibitors significantly reduced the virulence of pathogens in their corresponding plant hosts. The invention also provides for compositions comprising the same, methods of making the same, and methods of controlling plant disease.

The invention relates to the technical field of gene engineering, and particularly discloses streptococcus agalactiae WC1535 delta cps delta hylB as well as a construction method and application thereof. The streptococcus agalactiae WC1535 [delta] cps [delta] hylB is preserved in Guangdong Microbial Culture Collection Center on February 28, 2025, the preservation number is GDMCC NO.65955, and the address of the preservation unit is the 5th building, No. 59 building, No. 100 Courtyard, Xianlie Middle Road, Guangzhou. Compared with a traditional single-fragment deletion method, the toxicity of the deletion strain is not prone to being enhanced, and compared with a traditional injection immune vaccine, the gene deletion strain is used for preparing the tilapia oral live vaccine, the immune operation is simpler, and more labor cost is saved.

The invention discloses an application of osmundone in preparation of a medicine for treating methicillin-resistant staphylococcus aureus infectious pneumonia. Experimental results of an MRSA mouse pneumonia infection model show that osmundone can significantly reduce the bacterial load in lung tissues, alleviate excessive inflammatory response caused by infection and effectively improve the survival rate of mice. In addition, the invention discloses that osmundone reduces the adhesion and invasion ability of bacteria, reduces the toxicity of the bacteria and plays an antibacterial role by inhibiting the protein activity of staphylococcus aureus Sortase A (SrtA). Different from traditional antibiotics, osmundone does not apply survival pressure to bacteria, so that generation of drug resistance is not easily induced. On the basis, osmundone shows a good application prospect in the aspect of research and development of safe and effective MRSA infectious pneumonia treatment drugs.

The invention relates to the technical field of solenopsis invicta prevention and control, in particular to metarhizium palustris for preventing and controlling solenopsis invicta as well as engineering bacteria and application of the metarhizium palustris. The Metarhizium anisopliae provided by the invention is a strain which is separated from the field and has high toxicity to the solenopsis invicta, and can be used for preventing and treating the solenopsis invicta or constructing engineering bacteria for preventing and treating the solenopsis invicta. The engineering bacterium constructed by the invention has high toxicity to solenopsis invicta, and can enable the bombyx batryticatus infected with the solenopsis invicta to volatilize a large amount of a solenopsis invicta attractant longifolene, so that the bombyx batryticatus has a trapping and killing effect on the worker solenopsis invicta, and the sanitary behavior of the worker is obviously slowed down. When the engineering bacteria constructed by the invention are combined with a small amount of chemical insecticide bait, the control effect of wettable powder taking spores of the engineering bacteria as an active component on a multi-ant nest (a single-ant nest) of solenopsis invicta is 79% (58%) within 3 days, 93% (90%) within 7 days and 98% (98%) within 28 days, and the method has the advantages of safety, high efficiency and the like.

The invention discloses a construction method of a nocardia seriolae mycolic acid deficient strain, which belongs to the technical field of aquaculture prevention and control, and comprises the following steps: strain and material preparation, culture and genome extraction, upstream and downstream fragment cloning to construct deletion plasmids, competent cell preparation, electrotransformation and screening, and biological characteristic and toxicity analysis. The nocardia seriola seriola mycolic acid defect type strain is constructed and compared with a wild strain and a back-filling strain for research, the effect of the mycolic acid in the aspects of growth, form, toxicity and the like of thalli can be defined, the relationship between the mycolic acid and the pathogenicity of the thalli can be deeply known, and an important clue is provided for revealing the pathogenic mechanism of the nocardia seriola seriola.

The invention relates to a clostridium perfringens phage and application thereof. The bacteriophage is a clostridium perfringens bacteriophage P2ACQJS03 (wherein the clostridium perfringens bacteriophage P2ACQJS03), and the preservation number of the clostridium perfringens bacteriophage P2ACQJS03 in the China Center for Type Culture Collection (CCTCC) is CCTCC NO: M 20242430. The bacteriophage provided by the invention is a virulent bacteriophage separated from the nature, tests prove that the bacteriophage has no toxic effect on normal microbial flora, and the DNA of the bacteriophage cannot encode virulence genes, so that the bacteriophage is high in stability; the bacteriophage disclosed by the invention is wide in host range, and large-scale industrial production can be realized. The bacteriophage provides an excellent strain resource for developing a novel antibacterial preparation, and has a good application and development prospect.

The present invention relates to recombinant virulence attenuated Gram-negative bacterial strains and its use in a method of treating cancer in a subject.

The antibody disclosed by the invention can specifically target high-virulence klebsiella pneumoniae of different serotypes, and specifically targets klebsiella pneumoniae of K1 and K2 serotypes. The antibody disclosed by the invention can be combined with high-toxicity klebsiella pneumoniae extracellular capsular polysaccharide with high affinity, has very strong neutralizing activity on klebsiella pneumoniae, and can mediate complement and mature neutrophil to neutralize and kill bacteria in an in-vitro killing experiment, so that the bacterial density is reduced, and the killing effect is improved. The traditional Chinese medicine composition can effectively prevent and treat high-toxicity klebsiella pneumoniae clinical infection and effectively improve pulmonary infection, provides a way for solving the problems of klebsiella pneumoniae infection and multiple drug resistance, has remarkable significance in preventing, diagnosing and treating klebsiella pneumoniae infection, and has important value in development of a new generation of klebsiella pneumoniae medicine.

The invention relates to the technical field of microorganisms, and particularly discloses application of bifidobacterium animalis subsp. Lactis BAPerfectuus006 in improving qi deficiency and enhancing immunity. The bifidobacterium animalis subsp. Lactis BAPerfectuus006 provided by the invention is separated from intestinal tracts of healthy infants, has no drug resistance, no hemolytic activity, no pathogenicity, no virulence genes and transferable drug-resistant genes, and can be used for preparing the health-care food. The Jiangjing pill is a safe strain, can significantly improve the qi deficiency symptom, delay weight loss and reduce lactic acid accumulation, has better improvement effects in the aspects of qi deficiency symptom, thymus index, spleen index, holding power, suspension capacity and the like than Guangjing pill for tonifying middle-Jiao and Qi under the same condition, and also has the effect of enhancing immunity.

The present invention belongs to the field of biotechnology, and specifically relates to the use of the CD630_27900 gene in reducing the tolerance of Clostridium difficile. Knocking out the CD630_27900 gene can reduce the tolerance of Clostridium difficile to acidic environments and antibiotics and reduce its cytotoxicity; the sequence of the CD630_27900 gene is shown in SEQ ID NO.1; the antibiotics include ampicillin, metronidazole, amoxicillin, vancomycin, norfloxacin, cefoxitin, clindamycin and kanamycin. The research results of the present invention suggest that the CD630_27900 gene can be used as a target for inhibiting the drug resistance and reducing the toxicity of Clostridium difficile, providing a new idea for the treatment of Clostridium difficile infection (CDI).

The invention belongs to the technical field of biological control, and relates to a preparation method of prodenia litura nuclear polyhedrosis virus concentrate, which comprises the following steps: cultivating and hatching prodenia litura eggs at constant temperature, culturing the prodenia litura eggs in a dark place into 4-day-old larvae, performing virus infection and proliferation on the 4-day-old larvae, collecting and screening dead insects with strong toxicity and early death as virus semi-finished products, and refrigerating and storing the virus semi-finished products. And finally, preparing the virus semi-finished product into mother powder to obtain the prodenia litura nuclear polyhedrosis virus mother drug. The method comprises the following steps: extracting a parent drug sample to obtain a virus polyhedrosis, extracting a DNA comparison gene sequence of the virus polyhedrosis, prodenia litura nuclear polyhedrosis virus which is identified as prodenia litura nuclear polyhedrosis virus when the similarity between the virus polyhedrosis and Spodoptera litura Nucleoplydrovirus reaches 80% or above, and measuring various performance indexes, so that the prodenia litura nuclear polyhedrosis virus can be identified as prodenia litura nuclear polyhedrosis virus. The prodenia litura nuclear polyhedrosis virus mother drug prepared by the preparation method is used for preventing and treating lepidoptera pests such as prodenia litura, has important significance, has good development and application prospects, and has application value in preparation of insecticides and prevention and treatment of flat thorn moths.

Provided is a preparation method for recombinant botulinum toxin type A (BoNT / A), the method comprising: designing a BoNT / A amino acid sequence in a P0DP10 protein database; by using a homologous recombination method, inserting an His tag and an SUMO tag sequence into the N terminal of the BoNT / A amino acid sequence; and then performing cleavage between GG-M by means of a SUMO tag protease. A result shows that no amino acid residue of any tag and the SUMO sequence is present, so that the safety is remarkably improved. Comparative experiments and animal experiments show that the recombinant botulinum toxin type A polypeptide which is prepared, purified and activated on the basis of a bacterium body centrifugal supernatant has higher virulence, so that the effective dose during practical use is reduced, thus remarkably reducing side effects and stimulation and achieving higher safety.